Current progress in pharmacogenetics

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 824-831

  Blakey, John D ^a   Hall, Ian P ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Adverse drug effects; Genome wide association; Pharmacogenetics

Indexed keywords

ABACAVIR; ATORVASTATIN; AZATHIOPRINE; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; IRINOTECAN; NATALIZUMAB; NILOTINIB; RASBURICASE; RIFAMPICIN; TAMOXIFEN; VALPROIC ACID; VORICONAZOLE; WARFARIN;

ARTICLE; DECISION MAKING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; INDIVIDUALIZATION; PHARMACOGENETICS; PRIORITY JOURNAL; UREA CYCLE DISORDER; WHOLE BODY CT;

DRUG DESIGN; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENOME; HUMANS; MODELS, GENETIC; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79955845062     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03912.x     Document Type: Article

References (45)

1. Vessel ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989; 41: 535-52.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-4.
3. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
4. Aerssens J, Paulussen AD. Pharmacogenomics and the long QT syndrome. Pharmacogenomics 2008; 6: 259-70.
5. Flechtner I, de Lonlay P, Polak M. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. Diabetes Metab 2006; 32: 569-80.
6. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, Stricker BH, O'Connor GT, London SJ. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42: 45-52.
7. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, Huffman JE, Igl W, Albrecht E, Deloukas P, Henderson J, Granell R, McArdle WL, Rudnicka AR, Wellcome Trust Case Control Consortium, Barroso I, Loos RJ, Wareham NJ, Mustelin L, Rantanen T, Surakka I, Imboden M, Wichmann HE, Grkovic I, Jankovic S, Zgaga L, Hartikainen AL, Peltonen L, Gyllensten U, Johansson A, Zaboli G, Campbell H, Wild SH, Wilson JF, Gläser S, Homuth G, Völzke H, Mangino M, Soranzo N, Spector TD, Polasek O, Rudan I, Wright AF, Heliövaara M, Ripatti S, Pouta A, Naluai AT, Olin AC, Torén K, Cooper MN, James AL, Palmer LJ, Hingorani AD, Wannamethee SG, Whincup PH, Smith GD, Ebrahim S, McKeever TM, Pavord ID, MacLeod AK, Morris AD, Porteous DJ, Cooper C, Dennison E, Shaheen S, Karrasch S, Schnabel E, Schulz H, Grallert H, Bouatia-Naji N, Delplanque J, Froguel P, Blakey JD, NSHD Respiratory Study Team, Britton JR, Morris RW, Holloway JW, Lawlor DA, Hui J, Nyberg F, Jarvelin MR, Jackson C, Kähönen M, Kaprio J, Probst-Hensch NM, Koch B, Hayward C, Evans DM, Elliott P, Strachan DP, Hall IP, Tobin MD. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010; 42: 36-44.
8. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, Yang W, Cheng C, Pui CH, Relling MV, Evans WE. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-72.
9. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 2010; 103: 765-71.
10. Brinkmann U, Roots I, Eichbaum M. Pharmacogenetics of the human drug transporter gene MDR1. Drug Discov Today 2001; 6: 835-9.
11. Marsh S, Hopkins JM. Irinotecan pharmacogenomics. Pharmacogenomics 2010; 11: 1003-10.
12. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-12.
13. Sayers I, Hall IP. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep 2005; 5: 101-8.
14. 2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370: 2118-25.
15. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF Jr, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E. Effect of β2 adrenergic polymorphism on response to long-acting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-64.
16. 2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010; 181: 676-87.
17. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B. Efficacy of a new once daily long-acting beta agonist indacaterol versus twice daily formoterol in COPD. Thorax 2010; 65: 473-9.
18. Mackey J, McLeod D, Ragaz J, Gelmon K, Verma S, Pritchard K, Laing K, Provencher L, Charbonneau LF. Adjuvant targeted therapy in early breast cancer. Cancer 2009; 115: 1154-68.
19. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, Li X, Wilke RA, Rieder MJ, Williams PT, Ridker PM, Chatterjee A, Rotter JI, Nickerson DA, Stephens M, Krauss RM. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 2010; 5: e9763.
20. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, Wang L. Gemcitabine and arabinosylcytosine pharmacogenomics: genome-wide association and drug response biomarkers. PLoS ONE 2009; 4: e7765.
21. Ramoni RB, Saccone NL, Hatsukami DK, Bierut LJ, Ramoni MF. A testable model of nicotine dependence. J Neurogenet 2009; 23: 283-92.
22. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007; 104: 9758-63.
23. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-9.
24. The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genome-wide study. N Engl J Med 2008; 359: 789-99.
25. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
26. Kalari KR, Hebbring SJ, Chai HS, Li L, Kocher JP, Wang L, Weinshilboum RM. Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach. BMC Genomics 2010; 11: 357.
27. Estivill X, Armengol L. Copy number variants and common disorders. PLoS Genet 2007; 3: e190.
28. Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A. Causal relation between alpha synuclein gene duplication and familial Parkinsons disease. Lancet 2004; 364: 1167-69.
29. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27: 4406-12.
30. Hirschhorn JN. Genomewide association studies - illuminating biologic pathways. N Engl J Med 2009; 360: 1699-701.
31. Moore JH. A global view of epistasis. Nat Genet 2005; 37: 13-4.
32. Cantor RM. Prioritizing GWAS results: a review of the statistical methods and recommendations for their application. Am J Hum Gen 2010; 86: 6-22.
33. Saccone SF, Bolze R, Thomas P, Quan J, Mehta G, Deelman E, Tischfield JA, Rice JP. SPOT: a web-based tool for using biological databases to prioritize SNPs after a genome-wide association study. Nucleic Acids Res 2010; 38: W201-9.
34. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10: 392-404.
35. Rodenhiser D, Mann M. Epigenetics and human disease: translating basic biology into clinical applications. CMAJ 2006; 174: 341.
36. Ioannidis JP, Trikalinos TA. Early extreme contradictory research estimates may appear in published research: The Proteus phenomenon in molecular genetics research and randomised controlled trials. J Clin Epidemiol 2005; 58: 543-9.
37. Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008; 358: 637-9.
38. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42: 711-4.
39. Pirmohamed M, James S, Meakin SGreen C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
40. Pillans PI, Landsberg PG, Fleming AM, Fanning M, Sturtevant JM. Evaluation of dosage adjustment in patients with renal impairment. Intern Med J 2003; 33: 10-3.
41. Frueh FW, Goodsaid F, Rudman A, Huang SM, Lesko LJ. The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J 2005; 5: 218-20.
42. Meilleur KG, Littleton-Kearney MT. Interventions to improve patient education regarding multifactorial genetic conditions: a systematic review. Am J Med Genet A 2009; 149A: 819-30.
43. Prainsack B, Wolinsky H. Direct-to-consumer genome testing: opportunities for pharmacogenomics research? Pharmacogenomics 2010; 11: 651-5.
44. Kalow W. Both populations and individuals are evolutionary targets. Pharmacogenomics J 2002; 2: 12-4.
45. Tutton R, Corrigan OP, eds. Genetic Databases: Socio-Ethical Issues in the Collection and Use of DNA. London: Routledge, 2004.